

Application No. 09/693,558

Page 2

*Sub E'*

N-{2-[1-(4-phenylbutyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)-propionamide;  
N-{2-[1-(4-hydroxy-4-phenylbutyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)propionamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)-propionamide;  
N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(2-phenylethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)-acrylamide;  
N-[4-[1-(4-biphenylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(1-naphthylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(9-anthrylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(cyclohexylphenylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)-acrylamide;  
*2 cont*  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-(4-{1-[bis(4-fluorophenyl)methyl]piperidin-4-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-{1-[bis(2-chlorophenyl)methyl]piperidin-4-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(2-fluoro-pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(6-fluoro-pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide dihydrochloride;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide methanesulfonate;  
N-[4-(1-acetyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylacetyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(9-oxo-9H-fluoren-4-carbonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-methylsulfonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;

Application No. 09/693,558

Page 3

*Sub E1*

N-(4-{1-[bis(2-chlorophenyl)methyl]piperidin-4-yl}butyl)-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(9H-fluoren-9-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(1-naphthylaminocarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-  
propionamide;  
N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(2-fluoropyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(5-fluoropyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2-fluoro-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2,2-difluoro-3-(pyridin-3-yl)propionamide;  
*2 cont*  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)propionamide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)propionamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-5-(pyridin-3-yl)pentanoic acid amide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)pentanoic acid amide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-N-hydroxy-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2-hydroxy-3-(pyridin-3-yl)propionamide;  
N-{4-(1-diphenylmethylpiperidin-4-yl)butyl}-3-hydroxy-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-methylsulfonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(1-naphthylaminocarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-acetylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylacetylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;

Application No. 09/693,558

Page 4

Sub E1

N-{4-[1-(3,3-diphenylpropionyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(9-oxo-9H-fluoren-4-ylcarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(phenylpyridin-4-ylmethyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;  
N-[7-(1-diphenylmethylpiperidin-4-yl)heptyl]-3-(pyridin-3-yl)acrylamide;  
N-[8-(1-diphenylmethylpiperidin-4-yl)octyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-diphenylmethylpiperidin-4-yl)oxypropyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-benzylpiperidin-4-yl)oxypropyl]-3-(pyridin-3-yl)acrylamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[4-(4-diphenylmethylpiperazin-1-yl)-3-hydroxybutyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(4-diphenylmethylpiperazin-1-yl)propoxy]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylmethylpiperazin-1-yl)-4-oxobutyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(4-diphenylmethylpiperazin-1-yl)sulfonylpropyl]-3-(pyridin-3-yl)acrylamide;  
N-{2-[2-(4-diphenylmethylpiperazin-1-yl)ethoxy]ethyl}-3-(pyridin-3-yl)acrylamide;  
N-(4-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}but-2-enyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-{4-[(4-carboxyphenyl)phenylmethyl]piperazin-1-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-{4-[(4-aminophenyl)phenylmethyl]piperazin-1-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-2-(pyridin-3-yl)oxyacetamide;  
N-{5-[4-(9H-fluoren-9-yl)piperazin-1-yl]pentyl}-3-(pyridin-3-yl)acrylamide;  
N-{6-[4-(9H-fluoren-9-yl)piperazin-1-yl]hexyl}-3-(pyridin-3-yl)acrylamide;  
3-(pyridin-3-yl)-N-{4-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)piperazin-1-yl]butyl}acrylamide;  
3-(pyridin-3-yl)-N-{4-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]butyl}acrylamide;  
N-{4-[4-(naphthalen-1-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[5-(4-biphenyl-2-ylpiperazin-1-yl)pentyl]-3-(pyridin-3-yl)acrylamide;

2 cont

Application No. 09/693,558

Page 5

*butyl*  
*91*

N-[6-(4-biphenyl-2-yl)piperazin-1-yl]hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-yl)piperazin-1-yl]butyl]-2-(pyridin-3-yloxy)acetamide;  
N-[4-(4-biphenyl-2-yl)piperazin-1-yl]butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-propionamide;  
N-{5-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]pentyl}-3-(pyridin-3-yl)-acrylamide;  
N-{6-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]hexyl}-3-(pyridin-3-yl)-acrylamide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic amide;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{2-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)piperazin-1-yl]ethyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylacetyl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
*10<sup>2</sup> cont*  
N-[4-(4-benzoylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(2-aminobenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(4-carboxybenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(biphenyl-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9-oxo-9H-fluoren-4-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(furan-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(naphthalen-1-ylaminocarbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[4-(diphenylaminocarbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(naphthalen-2-sulfonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylphosphinonyl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-yl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;  
N-[4-(4-phenylpiperidin-1-yl)-butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(1H-indol-3-yl)piperidin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(2-oxo-2,3-dihydrobenzimidazol-1-yl)piperidin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzotriazol-1-yl)piperidin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;

Application No. 09/693,558

Page 6

*Sub E1*

N-{4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}-2-(pyridin-3-yloxy)acetamide;  
N-[4-(4,4-diphenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)propionamide  
dihydrochloride semi-isopropanol;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)piperidin-1-yl]butyl}-5-(pyridin-3-yl)pentanamide;  
N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)-  
propionamide;  
N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(4-diphenylphosphinoyloxypiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,6-dioxo-4-phenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
*2 cont*  
N-[4-(1,3-dioxo-4,5,6,7-tetraphenyl-1,3-dihydroisoindol-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(3-benzyl-2,4,5-trioxoimidazolidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3,10-trioxo-1,4,5,6,10,10a-hexahydroacnaphtho[1,8a-c]pyrrol-2-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3-phenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(3-pyridin-3-ylacryloylamino)butyl]-2,3,5,6-dibenzobicyclo[2.2.2]octan-7,8-dicarboximide;  
N-[4-(5-benzyliden-2,4-dioxothiazolidin-3-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzyl-2,6-dioxopiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(1-oxopyridin-3-yl)acrylamide;  
N-[6-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[2-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)ethyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[8,8-bis(4-fluorophenyl)octyl]-3-(pyridin-3-yl)acrylamide hydrochloride;  
N-[6-(3,3-diphenylureido)hexyl]-3-(pyridin-3-yl)acrylamide;

Application No. 09/693,558

Page 7

Sub E1

N-[4-(1-phenyl-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;  
N-(8-hydroxy-8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(3,3-diphenylureido)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(10,11-dihydrodibenzo[b,f]azepin-5-ylcarbonylamino)hexyl]-3-(pyridin-3-yl)acrylamide;  
3-(pyridin-3-yl)-N-[6-tosylaminoheptyl]acrylamide;  
N-[4-(1,1-dioxo-1-thia-2-azaacenaphthylene-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(6-hydroxy-6,6-diphenylhexyl)-3-(pyridin-3-yl)acrylamide;  
N-(6,6-diphenylhex-5-enyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(4,5-diphenylimidazol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(trans-2-phenylcyclopropylcarbonylamino)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(5-hydroxy-5,5-diphenylpentyl)-3-(pyridin-3-yl)acrylamide;  
N-(7-phenylheptyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-diphenylacetylaminobutyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(benzhydrylamino)butyl]-3-(pyridin-3-yl)acrylamide; and  
N-[4-{[2-(benzhydrylmethylamino)ethyl]methylamino}butyl]-3-(pyridin-3-yl)acrylamide.

2 cont

40.(Amended) The method of claim 50 comprising the additional administration of a further cancerostatic or immunosuppressive agent that is not a compound of formula Ia.

Sub E1

42.(Amended) The composition of claim 52 comprising a further cancerostatic or immunosuppressive agent that is not a compound of formula Ia.

43.(Amended) The composition of claim 52 where the compound(s) of formula Ia and the compound(s) of formula II - Vb are contained separately within the composition.

203

44.(Amended) The composition of claim 52 where the compound(s) of formula Ia and the compound(s) of formula II - Vb are present in separate dosage forms, and the dosage forms are packaged together for co-administration.

45.(Amended) The composition of claim 52 where:

*sch*  
*91*  
R<sup>21</sup> is selected from the group consisting of hydrogen, halogen, cyano, C<sub>1-6</sub> alkyl, trifluoromethyl, C<sub>1-6</sub> hydroxyalkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>2-7</sub> alkanoyloxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> aminoalkyl, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, formyl, alkoxycarbonyl, aminocarbonyl, (C<sub>1-6</sub> alkyl)aminocarbonyl, di(C<sub>1-6</sub> alkyl)aminocarbonyl, and carboxy;

R<sup>22</sup> is selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub> alkyl, trifluoromethyl, C<sub>1-6</sub> hydroxyalkyl, hydroxy, alkoxy, C<sub>2-7</sub> alkanoyloxy, C<sub>1-6</sub> aminoalkyl, amino, (C<sub>1-6</sub> alkoxy)carbonyl, aminocarbonyl, and carboxy;

*D3 cont*  
R<sup>23</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> hydroxyalkyl;

R<sup>24</sup> is selected from the group consisting of C<sub>1-6</sub> alkyl, C<sub>3-6</sub> alkenyl, C<sub>2-6</sub> hydroxyalkyl, C<sub>2-6</sub> alkoxyalkyl, and benzyl;

R<sup>26</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> hydroxyalkyl, C<sub>3-6</sub> alkoxyalkyl, C<sub>1-6</sub> aminoalkyl, C<sub>4-12</sub> dialkylaminoalkyl, and carboxymethyl;

when b is 1, R<sup>27</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> hydroxyalkyl, C<sub>3-6</sub> alkoxyalkyl, C<sub>1-6</sub> aminoalkyl, C<sub>4-12</sub> dialkylaminoalkyl, and carboxymethyl;

when b is 2, R<sup>27</sup> is C<sub>2-10</sub> alkylene in which a methylene group is optionally replaced by O, NH, or N-alkyl.

46.(Amended) The composition of claim 52 where the compound having vitamin PP activity or a prodrug thereof is selected from the group consisting of nicotinic acid, nicotinamide, and their pharmaceutically acceptable ester and amide derivatives, anionic, quaternary, and addition salts, N-oxides, and analogous thioxo derivatives, their isomers, and prodrugs thereof.

*sch*  
*91*  
48.(Amended) The composition of claim 51 where the compound having vitamin PP activity or a prodrug thereof is tryptophan.

*D4*  
49.(Amended) The composition of claim 52 where the compound(s) of formula Ia are selected from the group consisting of

N-[2-(1-benzylpiperidin-4-yl)ethyl]-1-(pyridin-3-yl)propionamide;

N-{2-[1-(2-phenylethyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)propionamide;

N-{2-[1-(4-phenylbutyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)propionamide;

N-{2-[1-(4-hydroxy-4-phenylbutyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)propionamide;

Application No. 09/693,558

Page 9

*Sub 1*

N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)propionamide;  
N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(2-phenylethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(4-biphenylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(1-naphthylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(9-anthrylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(cyclohexylphenylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)acrylamide;  
*Not cont*  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[4-[1-[bis(4-fluorophenyl)methyl]piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-[bis(2-chlorophenyl)methyl]piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(2-fluoro-pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(6-fluoro-pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide dihydrochloride;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide methanesulfonate;  
N-[4-(1-acetyl-piperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylacetyl-piperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(9-oxo-9H-fluoren-4-carbonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-methylsulfonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-[bis(2-chlorophenyl)methyl]piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;



Application No. 09/693,558

Page 10

*91*

N-{4-[1-(9H-fluoren-9-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-propionamide;  
N-{4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(1-naphthylaminocarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-propionamide;  
N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(2-fluoropyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(5-fluoropyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2-fluoro-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2,2-difluoro-3-(pyridin-3-yl)propionamide;  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)propionamide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)propionamide;  
*104 cont*  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-5-(pyridin-3-yl)pentanoic acid amide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)pentanoic acid amide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-N-hydroxy-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2-hydroxy-3-(pyridin-3-yl)propionamide;  
N-{4-(1-diphenylmethylpiperidin-4-yl)butyl}-3-hydroxy-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-methylsulfonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(1-naphthylaminocarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide;  
N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-acetylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylacetylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(3,3-diphenylpropionyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;

Application No. 09/693,558

Page 11

*Sub E1*

N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[4-[1-(9-oxo-9H-fluoren-4-ylcarbonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(phenylpyridin-4-ylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(6,11-dihydrodibenzo[b,c]oxepin-11-yl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[1-(6,11-dihydrodibenzo[b,e]flopipin-11-yl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[7-(1-diphenylmethylpiperidin-4-yl)heptyl]-3-(pyridin-3-yl)acrylamide;  
N-[8-(1-diphenylmethylpiperidin-4-yl)octyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-diphenylmethylpiperidin-4-yloxy)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-benzylpiperidin-4-yloxy)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
*Dt cont*  
N-[4-(4-diphenylmethylpiperazin-1-yl)-3-hydroxybutyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(4-diphenylmethylpiperazin-1-yl)propoxy]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylmethylpiperazin-1-yl)-4-oxobutyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(4-diphenylmethylpiperazin-1-sulfonyl)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[2-[2-(4-diphenylmethylpiperazin-1-yl)ethoxy]ethyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}but-2-enyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-{4-[(4-carboxyphenyl)phenylmethyl]piperazin-1-yl}butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-{4-[(4-aminophenyl)phenylmethyl]piperazin-1-yl}butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl]-2-(pyridin-3-yloxy)acetamide;  
N-[5-[4-(9H-fluoren-9-yl)piperazin-1-yl]pentyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-[4-(9H-fluoren-9-yl)piperazin-1-yl]hexyl]-3-(pyridin-3-yl)acrylamide;  
3-(pyridin-3-yl)-N-[4-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)piperazin-1-yl]butyl]acrylamide;  
3-(pyridin-3-yl)-N-[4-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]butyl]acrylamide;  
N-[4-[4-(naphthalen-1-yl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[5-(4-biphenyl-2-ylpiperazin-1-yl)pentyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(4-biphenyl-2-ylpiperazin-1-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-2-(pyridin-3-yloxy)acetamide;

Application No. 09/693,558

Page 12

*Sub E1*

N-[4-(4-biphenyl-2-yl)piperazin-1-yl]butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-propionamide;  
N-{5-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]pentyl}-3-(pyridin-3-yl)-acrylamide;  
N-{6-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]hexyl}-3-(pyridin-3-yl)-acrylamide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic amide;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{2-[4-(6,11-dihydrodibenzo[b,e]diazepin-11-yl)piperazin-1-yl]ethyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylacetyl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzoylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(2-aminobenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(4-carboxybenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
*Def cont*  
N-{4-[4-(biphenyl-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9-oxo-9H-fluoren-4-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(furan-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(naphthalen-1-ylaminocarbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[4-(diphenylaminocarbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(naphthalen-2-sulfonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylphosphinonylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-yl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;  
N-[4-(4-phenylpiperidin-1-yl)-butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(1H-indol-3-yl)piperidin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(2-oxo-2,3-dihydrobenzimidazol-1-yl)piperidin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzotriazol-1-yl)piperidin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}-2-(pyridin-3-yloxy)acetamide;  
N-[4-(4,4-diphenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;

Application No. 09/693,558

Page 13

Sub 61) N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)propionamide dihydrochloride semi-isopropanol;

N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)piperidin-1-yl]butyl}-5-(pyridin-3-yl)pentanamide;

N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)-propionamide;

N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;

N-[4-(4-diphenylphosphinoyloxy)piperidin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(2,6-dioxo-4-phenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1,3-dioxo-4,5,6,7-tetraphenyl-1,3-dihydroisoindol-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(3-benzyl-2,4,5-trioxoimidazolidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;

Def cont N-[4-(1,3,10-trioxo-1,4,5,6,10,10a-hexahydroacenaphtho[1,8a-c]pyrrol-2-yl)butyl]-3-(pyridin-3-yl)-acrylamide;

N-[4-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(2,5-dioxo-3-phenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[3-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)propyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(3-pyridin-3-ylacryloylamino)butyl]-2,3,5,6-dibenzobicyclo[2.2.2]octan-7,8-dicarboximide;

N-[4-(5-benzyliden-2,4-dioxothiazolidin-3-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(4-benzyl-2,6-dioxopiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[6-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)hexyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)propionamide;

N-[4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(1-oxopyridin-3-yl)acrylamide;

N-[6-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)hexyl]-3-(pyridin-3-yl)acrylamide;

N-[2-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)ethyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-[8,8-bis(4-fluorophenyl)octyl]-3-(pyridin-3-yl)acrylamide hydrochloride;

N-[6-(3,3-diphenylureido)hexyl]-3-(pyridin-3-yl)acrylamide;

N-[4-(1-phenyl-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)butyl]-3-(pyridin-3-yl)acrylamide;

N-(8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;


Application No. 09/693,558

Page 14

N-(8-hydroxy-8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(3,3-diphenylureido)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(10,11-dihydrodibenzo[b,f]azepin-5-ylcarbonylamino)hexyl]-3-(pyridin-3-yl)acrylamide;  
3-(pyridin-3-yl)-N-[6-tosylaminohexyl]acrylamide;  
N-[4-(1,1-dioxo-1-thia-2-azaacenaphthylen-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(6-hydroxy-6,6-diphenylhexyl)-3-(pyridin-3-yl)acrylamide;  
N-(6,6-diphenylhex-5-enyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(4,5-diphenylimidazol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(trans-2-phenylcyclopropylcarbonylamino)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(5-hydroxy-5,5-diphenylpentyl)-3-(pyridin-3-yl)acrylamide;  
N-(7-phenylheptyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-diphenylacetylaminobutyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(benzhydrylamino)butyl]-3-(pyridin-3-yl)acrylamide; and  
N-(4-{[2-(benzhydrylmethylamino)ethyl]methylamino}butyl)-3-(pyridin-3-yl)acrylamide.

Add claims 50 - 52 to read as follows:

50. The method of claim 38 where the cancerostatic or immunosuppressive agent is selected from the group consisting of compounds of formula Ia:



where:

R<sup>1</sup> is selected from the group consisting of hydrogen, fluorine, methyl, trifluoromethyl, and hydroxy;

$R^2$  and  $R^3$  are each hydrogen;

R<sup>4</sup> is hydrogen or hydroxy;

A is selected from the group consisting of ethylene, propylene, or butylene, each optionally substituted with hydroxy or one or two fluorine atoms, -OCH<sub>2</sub>-, -SCH<sub>2</sub>-, ethenylene, vinylene, and butadienylene;

Application No. 09/693,558

Page 15

*Sub E1*

D is selected from the group consisting of C<sub>2</sub> - C<sub>6</sub> alkylene and C<sub>2</sub> - C<sub>6</sub> alkenylene, where the double bond may also join D and E;


E is selected from the group consisting of pyrrolidine, piperidine, hexahydroazepine, and morpholine; and

*105 Cont*

G is selected from the group consisting of benzyl, phenethyl, fluorenylmethyl, anthrylmethyl, diphenylmethyl, fluorenyl, dihydrodibenzocycloheptenyl, furylmethyl, thienylmethyl, thiazolylmethyl, pyridylmethyl, benzothienylmethyl, quinolylmethyl, phenylthienylmethyl, phenylpyridylmethyl, dihydrodibenzoxepinyl, dihydrodibenzothiepinyl, acetyl, pivaloyl, phenylacetyl, diphenylacetyl, diphenylpropionyl, naphthylacetyl, benzoyl, naphthoyl, anthrylcarbonyl, oxofluorenylcarbonyl, oxodihydroanthrylcarbonyl, dioxodihydroanthrylcarbonyl, furoyl, pyridylcarbonyl, chromonylcarbonyl, quinolylcarbonyl, naphthylaminocarbonyl, dibenzylaminocarbonyl, benzylphenylaminocarbonyl, diphenylaminocarbonyl, indolin-1-ylcarbonyl, dihydrodibenzazepinyl-N-carbonyl, tetrahydroquinolinyl-N-carbonyl, tetrahydrobenzazepinyl-N-carbonyl, methanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, naphthalenesulfonyl, quinolinesulfonyl, and diphenylphosphinoyl, where the or each aromatic ring system may be independently substituted with one to three substituents selected independently from the group consisting of halogen, cyano, C<sub>1</sub> - C<sub>6</sub> alkyl, trifluoromethyl, C<sub>3</sub> - C<sub>8</sub> cycloalkyl, phenyl, benzyl, hydroxy, C<sub>1</sub> - C<sub>6</sub> alkoxy (optionally partially or completely fluorinated), benzyloxy, phenoxy, mercapto, C<sub>1</sub> - C<sub>6</sub> alkylthio, carboxy, C<sub>1</sub> - C<sub>6</sub> alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, C<sub>1</sub> - C<sub>6</sub> alkylamino, and di(C<sub>1</sub> - C<sub>6</sub> alkyl)amino, or two adjacent substituents together form methylenedioxy.

51. A pharmaceutical composition comprising:

(a) at least one compound selected from the group consisting of compounds of formula I:



where:

each of R<sup>1(i)</sup>, R<sup>2(i)</sup>, R<sup>3(i)</sup>, and R<sup>4(i)</sup> are independently selected from the group consisting of hydrogen, halogen, hydroxy, trifluoromethyl, cyano, aliphatic hydrocarbonyl residue optionally substituted with one or more functional groups and optionally interrupted by one or more heteroatoms, and aromatic hydrocarbonyl residue; or R<sup>1(i)</sup> and R<sup>2(i)</sup> together form a bridge;

Application No. 09/693,558

Page 16

*Sub E1*

k is 0 or 1;

A<sup>(0)</sup> and D<sup>(0)</sup> are independently a saturated or unsaturated optionally substituted aliphatic hydrocarbyl residue, optionally interrupted by a heteroatom or a functional group;

E is a bond or is a heterocyclic residue having one or two ring nitrogen atoms or one ring nitrogen atom and one ring oxygen atom, linked to D<sup>(0)</sup> and G through a ring nitrogen atom and a ring carbon atom or through two ring nitrogen atoms, and

G is selected from the group consisting of hydrogen, an aliphatic or araliphatic residue, an unsaturated or aromatic monocyclic or polycyclic carbocyclic residue, a saturated, unsaturated, or aromatic monocyclic or polycyclic heterocyclic residue, bonded directly or through a functional group derived from a carbon, nitrogen, oxygen, sulfur, or phosphorus atom,


and the stereoisomers or racemic or non-racemic mixtures of stereoisomers thereof,

*205 cont*

and the tautomers thereof when G is a heterocyclic aromatic ring or an aromatic ring substituted by a hydroxy, mercapto, or amino group, and the pharmacologically acceptable acid addition salts thereof;

- (b) a compound having vitamin PP activity or a prodrug thereof; and
- (c) at least one physiologically acceptable carrier.

52. The composition of claim 41 where the compound(s) of formula I are selected from the group consisting of compounds of formula Ia:



where:

R<sup>1</sup> is selected from the group consisting of hydrogen, fluorine, methyl, trifluoromethyl, and hydroxy;

R<sup>2</sup> and R<sup>3</sup> are each hydrogen;

R<sup>4</sup> is hydrogen or hydroxy;

A is selected from the group consisting of ethylene, propylene, or butylene, each optionally substituted with hydroxy or one or two fluorine atoms, -OCH<sub>2</sub>-, -SCH<sub>2</sub>-, ethenylene, vinylene, and butadienylene;